anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This clinical study uses the automated screening capabilities of the FocalPoint Primary Screening System (BD) for gynecologic cytology specimens (Pap tests) to allow for automated field of view (FOV) selection, digital image capture, and subsequent Internet-based transmission to a custom designed computer-based image reading station. The system utilizes liquid-based cytology preparations (ThinPrep, SurePath). In such a system, no skilled cytology human resources are necessary at the scanning site, and all expertise can be centralized. Pilot studies showed that the task was feasible to a clinically relevant standard of care. Phase 1 trials on preselected and seeded specimens confirmed this clinical standard. The phase 2 trials extend the concept to a prospectively enrolled population of patients from 2 sites (Walter Reed, Mass General) thereby testing the concept in a population of normal disease prevalence. The final phase 3 will be a larger study with intended use design, siting a screening device at the 121st Army Hospital in Korea and interpreting the specimen images in the US. In addition to the reading of the specimens, the system is designed to give immediate "loop closing" results back to each specimen's originating point immediate upon completion of the test.
553,904. Riboflavin. COMMERCIAL SOLVENTS CORPORATION. Nov. 13, 1940, No. 16446. Convention date, Oct. 24. Addition to 553,465 and 553,903. [Class 2 (iii)] [Also in Group VI] In the production of riboflavin, butyl alcohol and acetone by fermentation, especially with Clostridium Acetobutylicum (Weizmann) in which the amounts of iron, cobalt, nickel, copper, lead and zinc present in the mash are maintained sufficiently low to reduce or prevent the inhibiting effects of these metals on riboflavin formation as described in the parent Specification, the mashes are made from rice and corn. Preferably the rice is brown and unground, but polished rice may be used. Examples show the yields with various proportions of rice and corn. Specification 527,478 is referred to.
FIELD: medicine. SUBSTANCE: method involves diagnosing condition of organs and systems and exposing them concurrently to thermal and energetic factors. When acting upon eyelids in pupil projection and the middle of a line connecting the top points of superciliary arches with thermal factor, phytospecies is applied that comprises sage-brush leaves, Pol-pola leaves, Agromina leaves and stalks in 1:1:1 proportion in the amount of 15- 20 g grinded between fingers and formed as pyramid. The mass is fired. The energetic action is carried out by operator directing the energy flow towards the area having tetragonal boundary built between external eye angles, front center and nose tip. The place for applying action the operator determines from warmth, coolness, vibration, boom sensation or some tactile sensations deviating from norm in palms of the hands. Heat treatment is carried out until patient feels pricking feeling in the treatment area. Energetic treatment is carried out until light-violet and/or lilac and/or blue and/or white arises in patient keeping the eyes closed. Locomotor apparatus disorders being the case, the like heat treatment is applied to lumbosacral area. Diseases accompanied with benign tumor formation are treated with the like heat treatment applied to axillary areas. Diseases related to cerebral blood circulation disorders are treated with the like heat treatment applied to occipital tuberosity. Diseases related to sexual function disorders are treated with the like heat treatment applied to the ovarian or uterine projection area and/or to in female patients and to anterior and posterior prostate projection areas in male patient. Heat treatment is applied beside that with phyto- species having additional ingredients depending on particular disease in quantities of 0.5 of any ingredient amount in the basic species. EFFECT: enhanced effectiveness in adjusting energetic envelope. 6 cl
The management of cancer-related pain in patients with opioid use disorder (OUD) remains complex and often challenging for clinicians and patients. There is currently a paucity of data to guide best practices, and the evidence that exists is variably applied. In this hospital-based questionnaire, we sought to understand the variation in practice patterns among clinicians in palliative medicine, addiction medicine, and hospital medicine, in caring for this complex patient population. Sixty-two questionnaire responses were analyzed and variation was found in management of pain, as well as initiation or titration of buprenorphine and methadone. There was also a significant difference in postdischarge subspecialty follow-up. Furthermore, the findings suggest that buprenorphine and methadone may be underutilized in this population. Patients and clinicians may benefit from additional support and standardization of practices to best manage coexisting cancer-related pain and OUD.
Participants will be randomised to receive the medical food Glycosade as a starch load with a maximum dose of 100g. Glycosade to be taken as one dose.
The optimal anatomical plane (relative to the nerve) or the "goal" for local anesthetic (LA) injection during an ultrasound guided (USG) brachial plexus blockade (BPB) at the supraclavicular fossa is currently not known. USG BPB is often described as a "subfascial", "extra fascial", "intracluster", "interfascial", sub-perineural", "intraneural", "corner pocket" or "periplexus" injection. Although this suggests that the local anesthetic is injected into different tissue planes or fascial compartments, even if such planes do exist, as seen in other regions such as popliteal sciatic nerve are not clearly defined at the supraclavicular fossa. However, recently with the use of high definition ultrasound imaging for USG Selective trunk block (SeTB) and principal investigator has often observed distinct paraneural (fascial) sheath and fascial compartments surrounding the brachial plexus at the supraclavicular fossa. These connective tissue layers are also better delineated after the local anesthetic injection. The principal investigator believes these may be the connective tissue layers that previous researchers have referred to in different reports. Currently there are no published data demonstrating the paraneural sheath and fascial compartment surrounding the brachial plexus in-vivo. Principal investigator believes that this fascial layer and compartment influence the spread of LA during USG BPB around the individual elements of the brachial plexus at the supraclavicular fossa and therefore, these anatomical structures have to be delineated so as to improve the safety, success and quality of USG BPB. This study will involve reviewing archived high definition ultrasound images in audio video interleave format from all adult patients who had undergone USG SeTB for surgical anesthesia during upper extremity surgery from January 1, 2020 to June 30, 2021 to define the paraneural sheath and fascial compartments that surround the brachial plexus at the supraclavicular fossa.
The present invention provides an externally applied foot treatment ointment for the health care of the feet, which adopts notoginseng, musk, red sage root, clove and safflower as raw materials. The raw materials are watered, decorated and concentrated to make a paste, and the present invention comprises the raw materials of (by weight portion) 3 to 9 portions of notoginseng, 0.02 to 0.04 portion of musk, 4 to 9 portions of red sage root, 0.03 to 0.09 portion of clove and 0.5 to 0.9 portion of safflower. The externally applied foot treatment ointment of the present invention uses plant Chinese herbal medicines as effective ingredients, and is used safely and conveniently, and the skin can not be hurt. When the present invention is used, the medicine is applied to the foot part, and the foot part is massaged repeatedly to promote the skin to fully absorb the medicine. The externally applied foot treatment ointment of the present invention, which is usually used, can keep the skin lubricated, fine and tender, and the skin does not crack in winter. The present invention achieves the purposes of skin protection and disease treatment.
OBJECTIVES: I. Determine the objective response rate of a 120 hour continuous infusion of aminocamptothecin (9-AC) in chemotherapy naive patients with adenocarcinoma of the stomach or gastroesophageal junction. II. Characterize the nature of the toxicity of 9-AC on this schedule in this patient population. III. Determine the duration of response, time to progression, and survival of this patient population. IV. Study the pharmacokinetics and pharmacodynamics of 9-AC on this schedule in these patients.

OUTLINE: This is an open label, multicenter study. Patients receive intravenous aminocamptothecin by continuous infusion over 120 hours on days 1-5 and 8-12 followed by 1 week of rest for a 3 week cycle. Therapy continues for a minimum of 6 weeks (2 full cycles) unless there are unacceptable toxic effects or rapid disease progression. Dose escalation may occur in patients who complete 3 cycles of therapy without unacceptable toxicity. All patients will be followed for survival.

PROJECTED ACCRUAL: This study will accrue 14-40 patients within 18 months.
Avatrombopag will be initiated at a dose of 20 mg, once daily in the open-label extension (OLE) period. The avatrombopag dose will be titrated up or down in accordance with the participant's individual response, within the range of a minimum of 5 mg and a maximum of 50 mg for up to 48 weeks.
FIELD: organic chemistry. SUBSTANCE: products: derivatives of diaminotrifluoromethylpyridine of the formula      where radicals have the corresponding values. Reagent 1: compound of the formula      at the corresponding values of radicals. Reagent 2: compound of the formula Z-CW 1 R 1  where W 1  and R 1  have values indicated above, and Z - desplitting group. Reaction conditions: the end product is isolated as a free form or as a salt of alkaline or alkaline-earth metal. Synthesized compounds were used in medicine. EFFECT: improved method of synthesis. 6 cl, 13 tbl
Pneumonia is the leading cause of death from nosocomial infections. Intubation and mechanical ventilation greatly increase the risk of ventilator associated pneumonia (VAP) which is highest in trauma, burn, neurosurgical and surgical patients. Oral bacteria have been shown to be responsible for the development of VAP since the endotracheal tube provides a pathway for direct entry of bacteria from the oropharynx to the respiratory tract. Therefore, reducing the number of microorganisms in the mouth reduces the pool of organisms available for translocation to and colonization of the lung. The Tri-Service Oral Health Survey showed that military recruits had inferior oral health when compared to their civilian cohorts. Further, oral hygiene is likely to deteriorate in combat situations, increasing oral microbial flora. Intubation of combat casualties in the future will likely be performed in the field by the EMT-B trained combat medic (91W) under adverse conditions. Therefore, interventions to reduce oral microbial flora with intubation are attractive to reduce the incidence of VAP in combat casualties. This study will test the effect of a single peri-intubation oral intervention on oral microbial flora and the development of VAP in traumatic injury. Two hundred trauma patients requiring endotracheal intubation will be randomly assigned to either the intervention or control group over an 18-month data collection period. Data related to oral microbial flora (measured by semi-quantitative oral culture) and VAP (measured by the clinical pulmonary infection score-CPIS) will be obtained on study admission, at 24 (oral culture data only), 48 and 72 hours after intubation. The exact Wilcoxon two-sample one-sided test will be used to test for difference between groups. CPIS data will be compared using an analysis of covariance model. Covariates such as baseline oral culture category, trauma-injury and severity score (TRISS), illness severity (APACHE III) and frequency and timing of usual oral care will also be included. The findings from this study will be the first report of an empirically based peri-intubation oral intervention to reduce VAP and can be easily applied to the care of traumatic injury in both combat and civilian casualties.
PURPOSE:To provide a carcinostatic agent having low toxicity and excellent carcinostatic activity and containing one or more specific furan-ring acids existing in the liver or ovary, etc., of fish as active components. CONSTITUTION:The objective carcinostatic agent contains a furan-ring fatty acid of formula (R1 and R2 are H or CH3; n is integer of 1-8; m is integer of3-16) as an active component. Especially, a compound wherein both R1 and R2 are CH3 e.g. 12,15-epoxy-13,14-dimethyl-12,14-octadecadienoic acid, etc., has strong carcinostatic activity. It is administered as it is or in an arbitrary form such as emulsion, tablet, solution, etc. The compound of formula exhibits excellent carcinostatic effect against various carcinomas of mouse, is available from natural animal and vegetable and exhibits no grave side effect.
PURPOSE: This systematic review evaluated the efficacy of therapeutic interventions on improving swallow, respiratory, and cough functions in Parkinson's disease (PD).
METHOD: A PRISMA systematic search was implemented across six databases. We selected studies reporting pre- and post-assessment data on the efficacy of behavioural therapies with a swallow or respiratory/cough outcome, and excluded studies on medical/surgical treatments or single-session design. Cross-system outcomes across swallow, respiratory, and cough functions were explored. Cochrane's risk of bias tools were utilised to evaluate study quality.
RESULT: Thirty-six articles were identified and further clustered into four treatment types: swallow related (n = 5), electromagnetic stimulation (n = 4), respiratory loading (n = 20), and voice loading (n = 7) therapies. The effects of some behavioural therapies were supported with high-quality evidence in improving specific swallow efficiency, respiratory pressure/volume, and cough measures. Only eleven studies were rated with a low risk of bias and the remaining studies failed to adequately describe blinding of assessors, missing data, treatment adherence, and imbalance assignment to groups.
CONCLUSION: Behavioural therapies were diverse in nature and many treatments demonstrated broad cross-system outcome benefits across swallow, respiratory, and cough functions. Given the progressive nature of the condition, the focus of future trials should be evaluating follow-up therapy effects and larger patient populations, including those with more severe disease.
Iron-doped apatite nanoparticles (IDANPs) are useful for the prevention, treatment, or alleviation of signs or symptoms associated with viral activation or infection. IDANPs have demonstrated a significant influence over herpes simplex virus 1 (HSV-1) infection of two mammalian cell lines. Specifically, IDANPs decreased HSV-1 infection of African Green Monkey kidney epithelial (Vero) cells by 84% and HSV-1 infection of human lung bronchus (BEAS-2B) cells by 71%. IDANPs consist of hydroxyapatite (HA) doped with iron. HA is a mineral known to be biocompatible and analogous to the inorganic constituent of mammalian bone and teeth and has been approved by the Food and Drug Administration (FDA) for many applications in medicine and dentistry. Lactate Dehydrogenase (LDH) and XTT (2,3-Bis 2-methoxy-4-nitro-5-sulfophenyl-2H-tetrazolium-5-carboxanilide inner salt) cytotoxicity assays revealed that IDANPs are largely non-toxic to Vero, BEAS-2B, and human cervical cancer (HeLa) cells lines. HSV-1 afflicted individuals in the United States have been estimated as high as ⅔ the population. Because IDANPs dramatically decrease HSV-1 infection and are largely non-toxic, their application as an antiviral agent is evident. Further, although iron(III) alone has been shown to diminish replication of deoxyribonucleic acid (DNA)- and ribonucleic acid (RNA)-containing viruses, IDANP cytotoxicity studies indicate that encasement and delivery of iron within an apatite unit cell structure diminishes significantly, and in some cases eliminates, cytotoxicity posed by the introduction of iron(III) alone.
Participants were asked to maintain their normal work practices and received no intervention. Participants were offered the opportunity to have a sit-stand workstation installed for 8 weeks after all data collection.
The invention discloses a traditional Chinese medicinal composition for treating prostatitis. The traditional Chinese medicinal composition is prepared by compounding phyllanthus urinaria with dandelions, scutellaria barbata, nephrolepis auriculata, creeping oxalis, semen plantaginis, gardenia, saururus chinensis, semen cuscutae, vervain and oldenlandia diffusa according to a certain weight ratio. The raw materials are natural Chinese herbal medicine with the effect of removing stagnation, promoting dieresis, relieving swelling, clearing heat, promoting blood circulation and relieving pain. Through combination of the herbs, the effect of removing phlegm, dissolving turbidity, clearing heat, promoting dieresis, promoting blood circulation, removing stasis and relieving swelling and pain is achieved. The traditional Chinese medicinal composition for treating urethritis can treat the prostatitis effectively on the basis of pathology, and usually, patients can recover in about 15 days. Simplicity in compatibility is achieved, medicinal source is extensive, and cost is low.
Approximately 1500 candidates per year will respond to advertisements and will complete preliminary telephone screening without identifiers. Appropriate candidates will be given appointment times and on arrival will undergo the consent process for evaluation. A complete medical, social, psychiatric, and drug use history will be obtained. Subjects fulfilling general health inclusion requirements will then be offered an appropriate study for which the specific consent will be obtained. The evaluation period will be no more than one day with all results evaluated within the two following days. Acceptable candidates will then be invited to complete the study specific consent.
Rheumatoid arthritis (RA) and osteoporosis are two chronic disorders that are often seen together. RA is an autoimmune disorder that causes pain and inflammation in the joints, while osteoporosis is a disorder in which the bones become weak and fragile. Risk factors for bone loss in RA include disease activity, longer disease duration, erosive disease, autoantibody positivity, and joint damage leading to impaired physical activity. Recent research has shown that there is a complex interplay between immune cells, cytokines, and bone remodeling processes in both RA and osteoporosis. The bone remodeling process is regulated by cytokines and immune system signaling pathways, with osteoclasts activated through the RANK/RANKL/OPG pathway and the Wnt/DKK1/sclerostin pathway. Understanding these mechanisms can aid in developing targeted therapies for treatment of osteoporosis in RA patients. Current pharmacological approaches include anti-osteoporotic drugs such as bisphosphonates, denosumab, teriparatide, abaloparatide, raloxifene, and romosozumab. Conventional disease-modifying antirheumatic drugs such as methotrexate and biologicals including TNF inhibitors, IL-6 inhibitors, rituximab, and abatacept lower disease activity in RA and can improve bone metabolism by reducing inflammation but have limited impact on bone mineral density. This review will shed light on the relationship between osteoporosis and rheumatoid arthritis as well as the various factors that influence the onset of osteoporosis in RA patients. We also explore several treatment approaches to effectively managing osteoporosis in RA patients.
PURPOSE: First-generation bone bridges (BBs) have demonstrated favorable safety and audiological benefits in patients with conductive hearing loss. However, studies on the effects of second-generation BBs are limited, especially among children. In this study, we aimed to explore the surgical and audiological effects of second-generation BBs in patients with bilateral congenital microtia.
METHODS: This single-center prospective study included nine Mandarin-speaking patients with bilateral microtia. All the patients underwent BCI Generation 602 (BCI602; MED-EL, Innsbruck, Austria) implant surgery between September 2021 and June 2023. Audiological and sound localization tests were performed under unaided and BB-aided conditions.
RESULTS: The transmastoid and retrosigmoid sinus approaches were implemented in three and six patients, respectively. No patient underwent preoperative planning, lifts were unnecessary, and no sigmoid sinus or dural compression occurred. The mean function gain at 0.5-4.0 kHz was 28.06 ± 4.55-dB HL. The word recognition scores improved significantly in quiet under the BB aided condition. Signal-to-noise ratio reduction by 10.56 ± 2.30 dB improved the speech reception threshold in noise. Patients fitted with a unilateral BB demonstrated inferior sound source localization after the initial activation.
CONCLUSIONS: Second-generation BBs are safe and effective for patients with bilateral congenital microtia and may be suitable for children with mastoid hypoplasia without preoperative three-dimensional reconstruction.
Almotriptan malate (AXERT®) is approved for the treatment of migraine headache, with or without aura, in adults. This is a multicenter, randomized, double-blind, placebo-controlled, parallel group study of adult patients with a diagnosis of migraine headache, with or without aura. Patients will be randomized (like with the toss of a coin) to receive almotriptan malate (AXERT®) or placebo for the treatment of 3 consecutive qualifying migraine headaches. After screening, patients will leave the study center with blinded study medication and an electronic subject diary (Personal Digital Assistant \[PDA\]). Patients will self-dose with study medication as soon as headache pain of any intensity begins (that resembles their usual migraine), but no later than 1 hour after headache pain begins. Patients will use their PDAs to record assessments such as pain intensity, symptom severity and ability to function as related to the headaches. The primary hypothesis of this study is that the percentage of patients who are pain free two hours after taking study drug at the earliest onset of headache pain is greater in the almotriptan malate (AXERT®) 12.5mg group than in the placebo group and almotriptan malate (AXERT®) is generally well-tolerated.

Almotriptan malate (AXERT®) 12.5 milligrams or placebo tablets, one by mouth at the beginning of migraine pain (within 1 hour) for 3 consecutive migraine headaches